Imbruvia
J&J’s Darzalex combination treatment for untreated multiple myeloma recommended by NICE
Around 33,000 people in the UK are currently living with multiple myeloma, an incurable type of blood cancer
NICE recommends axunio’s Axhidrox cream for adults with severe hyperhydrosis
Excessive sweating affects 1-5% of the population and can have a substantial impact on quality of life
NICE recommends treatments for mantle cell lymphoma and chronic lymphocytic leukaemia
The treatments are for eligible adults in England and Wales
Johnson & Johnson announces change in senior leadership role
Tom Cavanaugh has been appointed as Executive Vice President, Worldwide Chairman Innovative Medicine
Johnson & Johnson commits $5.5bn to end remaining talc litigation
The resolution comes after plaintiffs were unable to prove that J&J’s talc products caused their ovarian cancer
J&J’s Erleada prostate cancer study shows significant reduction in risk of metastasis
Erleada plus hormone therapy significantly improved key short- and long-term clinical outcomes
NICE recommends Genmab’s Tivdak for recurrent or metastatic cervical cancer
It is estimated that 3,300 women are diagnosed with cervical cancer in the UK each year
J&J’s Icotyde approved by US FDA for plaque psoriasis
Plaque psoriasis affects over 125 million people worldwide
J&J’s nipocalimab gets FDA Fast Track designation for lupus
The autoimmune disease affects approximately three to five million people globally
Johnson & Johnson’s Darzalex Faspro regimen receives FDA approval for multiple myeloma
Multiple myeloma has an average five-year survival rate of 59.8% and is currently incurable
Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD
Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed
Johnson & Johnson’s Rybrevant shows positive effects in difficult-to-treat colorectal cancer
Colorectal cancer accounts for around 10% of all cancer cases globally, with an increase in diagnoses in younger people